Format

Send to

Choose Destination
Expert Opin Drug Deliv. 2011 Apr;8(4):485-504. doi: 10.1517/17425247.2011.558082. Epub 2011 Feb 22.

Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis.

Author information

1
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Abstract

INTRODUCTION:

Angiogenesis is essential to human biology and of great clinical significance. Excessive or reduced angiogenesis can result in, or exacerbate, several disease states, including tumor formation, exudative age-related macular degeneration (AMD) and ischemia. Innovative drug delivery systems can increase the effectiveness of therapies used to treat angiogenesis-related diseases.

AREAS COVERED:

This paper reviews the basic biology of angiogenesis, including current knowledge about its disruption in diseases, with the focus on cancer and AMD. Anti- and proangiogenic drugs available for clinical use or in development are also discussed, as well as experimental drug delivery systems that can potentially improve these therapies to enhance or reduce angiogenesis in a more controlled manner.

EXPERT OPINION:

Laboratory and clinical results have shown pro- or antiangiogenic drug delivery strategies to be effective in drastically slowing disease progression. Further research in this area will increase the efficacy, specificity and duration of these therapies. Future directions with composite drug delivery systems may make possible targeting of multiple factors for synergistic effects.

PMID:
21338327
PMCID:
PMC3959173
DOI:
10.1517/17425247.2011.558082
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center